drugset / Trial / NCT00006262

Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer

NCT00006262

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analogue in treating patients who have refractory stage III or stage IV ovarian epithelial cancer.

Timeline

Start
2000-07
Primary completion
2001-09
Completion
2001-09

Drugs

EvaluationDrugModalityDoseRoute
Subject becatecarin Other / unclassified Intravenous

Indications